Abstract:Aim: To evaluate the anti-cancer effects of a new sulfonamide derivative, 2-(N-(3-chlorophenyl)-4-methoxyphenylsulfonamido)-N-hydroxypropanamide (MPSP-001). Methods: Human cancer cell lines (HepG2, THP-1, K562, HGC-27, SKOV3, PANC-1, SW480, Kba, HeLa, A549, MDA-MB-453, and MCF-7) were examined. The cytotoxicity of MPSP-001 was evaluated using the WST-8 assay. Cell cycle distribution was examined with flow cytometry. Mitotic spindle formation was detected using immunofluorescence microscopy. Apoptosis-related proteins were examined with Western blot using specific phosphorylated protein antibodies. Competitive tubulin-binding assay was performed to test whether the compound competitively bound to the colchicine site. Molecular docking was performed to explore the possible binding conformation. Results: MPSP-001 potently inhibited the growth of the 12 different types of human cancer cells with the IC 50 values ranging from 1.9 to 15.7 μmol/L. The compound exerted potent inhibition on the drug-resistant Kb/VCR and MCF-7/ADR cells, as on Kba and MCF-7 cells. In HeLa, HGC-27, A549, and other cells, the compound (5 μmol/L) caused cell cycle arrest at the G 2 /M phase, and subsequently induced cell apoptosis. In Hela cells, it prevented the mitotic spindle formation. Furthermore, the compound dose-dependently inhibited polymerization of tubulin in vitro , and directly bound to the colchicine-site of β-tubulin. Molecular docking predicted that the compound may form two hydrogen bonds to the binding pocket. The compound showed synergistic effects with colchicine and taxol in blocking mitosis of HeLa cells. Conclusion: MPSP-001 shows a broad-spectrum of anti-tumor efficacy in vitro and represents a novel structure with anti-microtubule activity.

A New Small-Molecule Aurora B Inhibitor Shows Antitumor Activity in Human Cancer Cell Lines

In Vitro and in Vivo Characterization of a Benzofuran Derivative, a Potential Anticancer Agent, As a Novel Aurora B Kinase Inhibitor.

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.

3-Hydroxyflavone inhibits endogenous Aurora B and induces growth inhibition of cancer cell line

S39, A Novel Aurora B Kinase Inhibitor, Shows Potent Antineoplastic Activity in Human Hela Cervical Cancer Cell Line

Orally Active Aurora A/B Kinase Inhibitor, AM‐005, Suppresses the Growth of Human Colon Carcinoma Cells

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors

The Synthesis and Anti-Tumour Properties of Novel 4-Substituted Phthalazinones As Aurora B Kinase Inhibitors.

Synthesis and Biological Evaluation of 2,4-Diaminopyrimidines As Selective Aurora A Kinase Inhibitors.

L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in Vitro and in Vivo

Synthesis and Biological Evaluation of Aurora Kinases Inhibitors Based on N-trisubstituted Pyrimidine Scaffold

A Novel Small-Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor–Initiating Cells and Overcomes Drug Resistance

Discovery of Novel 2,4-Disubstituted Pyrimidines As Aurora Kinase Inhibitors.

Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.

Discovery of 4-Aminoquinazoline—urea Derivatives As Aurora Kinase Inhibitors with Antiproliferative Activity

Design, Synthesis, Biological Evaluation of 6-(2-amino-1h-benzo[d]imidazole-6-yl)quinazolin-4(3h)-one Derivatives As Novel Anticancer Agents with Aurora Kinase Inhibition.

Synthesis and Quantum Chemical Studies of New 4-Aminoquinazoline Derivatives As Aurora A/B Kinase Inhibitors

Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins

Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo.